Effect of simvastatin in CAPD patients with hypercholesterolemia.

A. De Vecchi, A. Scalamogna, M. Paparella, M. Colombini, A. Rovellini, C. Pini, C. Castelnovo

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of simvastatin on serum total and HDL cholesterol and total triglyceride levels in 20 hypercholesterolemic patients on CAPD treatment was studied. The drug was given at the initial dose of 10 mg/day which was doubled up to 40 mg/day. Two non-compliant patients stopped the drug in the first week of treatment. One patient had vomiting and stopped simvastatin. One patients reduced the dose from 20 to 10 mg/day because of increase in CPK level. The study was completed in 16 patients. Serum cholesterol decreased from 318 +/- 39 to 208 +/- 34 mg/dl (p <0.001), triglyceride from 317 +/- 129 to 278 +/- 160 mg/dl and HDL cholesterol from 43 +/- 13 to 35 +/- 11 mg/dl. The effective does was 10 mg/day in 4 cases, 20 mg/dl in 7 and 40 mg/dl in 5. In CAPD patients, simvastatin is safe and effective in lowering serum cholesterol. The clinical significance of the decrease in HDL cholesterol and its possible effect on clinical outcome are still unknown.

Original languageEnglish
Pages (from-to)331-333
Number of pages3
JournalAdvances in peritoneal dialysis. Conference on Peritoneal Dialysis
Volume8
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effect of simvastatin in CAPD patients with hypercholesterolemia.'. Together they form a unique fingerprint.

Cite this